Transcriptional hallmarks of cancer cell lines reveal an emerging role of branched chain amino acid catabolism
Artikel i vetenskaplig tidskrift, 2017

A comparative analysis between cancer cell lines and healthy dividing cells was performed using data (289 microarrays and 50 RNA-seq samples) from 100 different cancer cell lines and 6 types of healthy stem cells. The analysis revealed two large-scale transcriptional events that characterize cancer cell lines. The first event was a large-scale up-regulation pattern associated to epithelial-mesenchymal transition, putatively driven by the interplay of the SP1 transcription factor and the canonical Wnt signaling pathway; the second event was the failure to overexpress a diverse set of genes coding membrane and extracellular proteins. This failure is putatively caused by a lack of activity of the AP-1 complex. It was also shown that the epithelial-mesenchymal transition was associated with the up-regulation of 5 enzymes involved in the degradation of branched chain amino acids. The suitability of silencing one of this enzymes (branched chain amino acid transaminase 2; BCAT2) with therapeutic effects was tested experimentally on the breast cancer cell line MCF-7 and primary cell culture of breast tumor (BCC), leading to lower cell proliferation. The silencing of BCAT2 did not have any significant effect on ASM and MCF10A cells, which were used as models of healthy dividing cells.

Enrichment Analysis

Migration

Proliferation

Pancreatic-Cancer

Stem-Cells

Large Gene Lists

SP1

NFAT

AP-1

Författare

I. Antanaviciute

Institute of Cardiology Lithuanian

V. Mikalayeva

Institute of Cardiology Lithuanian

I. Cesleviciene

Institute of Cardiology Lithuanian

G. Milasiute

Institute of Cardiology Lithuanian

V. A. Skeberdis

Institute of Cardiology Lithuanian

Sergio Velasco

Chalmers, Biologi och bioteknik, Systembiologi

Scientific Reports

2045-2322 (ISSN)

Vol. 7 1 Article no 7820 - 7820

Ämneskategorier

Medicinteknik

Cell- och molekylärbiologi

DOI

10.1038/s41598-017-08329-8

Mer information

Skapat

2017-10-07